CEL-SCI Corporation (CVM): Significant Potential, but a Long Way from Results

Mann mit Smartphone und Tablet (Symbolbild). © metamorworks / iStock / Getty Images Plus / Getty Images

PR Newswire

NEW YORK, March 27, 2014

NEW YORK, March 27, 2014 /PRNewswire/ -- Across the globe, there are over 13 million new cancer cases each year. By 2030, it is estimated by the International Agency for Research on Cancer (IARC) that there will be approximately 21.4 million new cancer cases and 13.2 million cancer deaths worldwide. Some of the more common (and deadly) forms of cancer are head and neck cancer, which account for approximately 600,000 new cases worldwide each year and result in a five-year survival rate of around 30%. One company that is actively trying to fight this disease is CEL-SCI Corporation (NYSE-MKT: CVM).

CEL-SCI Corporation (CVM) is engaged in the research and development of drugs and vaccines, and is currently in a Phase III clinical trial directed at using the immune system to produce an anti-tumor immune response against primary head and neck cancer. Multikine (Leukocyte Interleukin, Injection) has been cleared by regulators in eleven countries around the world, including the FDA in the US, for this Phase III trial following encouraging results from both Phase I and II trials. Multikine is a different kind of investigational therapy in which immunotherapy is given to cancer patients first (prior to them receiving any conventional treatment for cancer, i.e. surgery, radiation, and/or chemotherapy).

A full in-depth analyst report on CVM that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/CVM-AnalystReport

copy and paste to browser may be required

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of companies mentioned to be materially different from the statements made herein.

ARIVA.DE Börsen-Geflüster

Kurse

Cel-Sci

0,00%

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Michael Maggi, Chartered Financial Analyst. An outsourced research services provider represented by Michael Maggi, CFA, provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Maggi, CFA. Small Cap Street, LLC is the party responsible for issuing the press release and for hosting the full analyst report on smallcapir.com. Michael Maggi, Chartered Financial Analyst, is the author of research report. This information is submitted to increase awareness for mentioned companies to the public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapstreet.com. For any urgent concerns or inquiries, please contact us at admin@smallcapstreet.com.

NOT FINANCIAL ADVICE

Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street, LLC has compensated Michael Maggi, CFA, two hundred dollars for the right to disseminate analyst report. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. Views expressed in analyst report are not the opinion of Small Cap Street, LLC.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Small Cap Street, LLC

Mehr Nachrichten zur Cel-Sci Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.